• Evolus to Report Fourth Quarter and Year End 2020 Results and Provide Business Update

    Source: Nasdaq GlobeNewswire / 23 Mar 2021 08:20:56   America/Chicago

    NEWPORT BEACH, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its fourth quarter and year end 2020 financial results and provide a business update conference call and live audio webcast on Wednesday, March 24, 2021.

    Management will host a conference call and live webcast to discuss Evolus’ financial results at 4:30 p.m. ET. A question and answer session will follow management remarks.

    The dial-in numbers for the conference call are (866) 916-2317 for domestic callers and (703) 925-2662 for international callers.  The conference ID is 7378855.

    A replay of the call will be available following its completion through March 31, 2021. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers and use the replay conference ID 7378855.

    A live audio webcast of the call will be available on the Investor Relations page of the Evolus, Inc. website, https://investors.evolus.com. A replay of the webcast will be archived on Evolus' website for 30 days following the completion of the call.

    About Evolus, Inc.

    Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at: http://www.evolus.com.

    Jeuveau® is a registered trademark of Evolus, Inc.

    Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

    Evolus, Inc. Contacts:

    Investor Contact:

    Ashwin Agarwal
    Vice President, Finance, Investor Relations & Treasury
    Tel: +1-949-284-4559
    Email: IR@Evolus.com   

    Media Contact:

    Crystal Muilenburg
    Chief Marketing Officer
    Tel: +1-949-284-4506
    Email: media@evolus.com 


    Primary Logo

Share on,